Concepedia

Publication | Open Access

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

DOIFull Paper Access

11

Citations

14

References

2022

Year

Debra Tompson, Mark Whitaker, Rennan Pan, Geoffrey Johnson, Teresa Fuller, Vanessa Zann, Litza McKenzie, Kathy Abbott-Banner, Simon Hawkins, Marcy Powell
Pharmaceutical Research

Abstract

The DiffCORE technology overcame the food effect vulnerability observed with the matrix monolithic formulation. The MR-16 h formulation was selected for further clinical development as a QD dosing regimen (NCT03649412 September 26, 2018).

References

YearCitations

Page 1